Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Changes include new information about risks associated with dolutegravir during pregnancy and removal of older drugs owing to toxicities.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
Researchers examined outcomes among a group of people in middle- and low-income nations who switched to the integrase inhibitor.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
Tivicay was associated with a higher rate of viral suppression at delivery compared with Sustiva.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
Timothy Brown may have company after a man’s virus went into remission following an HIV-resistant stem cell transplant to treat his cancer.
Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.
This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Beginning six months of treatment within two days following infection prevented viral rebound in at least some animals in a recent study.
However, the regimen appears much less potent for those who aren’t virally suppressed.
Biktarvy has a lower rate of adverse health events, according to 96-week data.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.